Cancer immunotherapy has transformed from experimental research into a clinical standard, with the FDA approving 156 such therapies since 2011 to train the body’s immune system to destroy malignant cells. According to the Cancer Research Institute (CRI), real-world utilization of these treatments has expanded more than 20-fold, now providing viable options for over 20 solid tumor types and five blood cancers. For patients with advanced, stage 4 diagnoses who have exhausted traditional chemotherapy or radiation, these breakthroughs represent a shift from palliative care to potential remission.
How Immunotherapy Changes Patient Outcomes
Immunotherapy operates by identifying and neutralizing cancer cells that previously evaded the immune system’s natural defenses. Clinical data tracked by the CRI demonstrates that for many patients, this approach provides a second chance when conventional methods fail.
- Oswald Peterson: Diagnosed with stage 4 lung cancer in early 2017, Peterson received pembrolizumab (Keytruda) and reached a cancer-free status by July 2017.
- Adrienne Skinner: After three failed chemotherapy regimens for stage 4 ampullary cancer, Skinner enrolled in a clinical trial for pembrolizumab at Johns Hopkins. A biopsy confirmed her tumor was eradicated within three months; she remains cancer-free more than a decade later.
- Jenney Bitner: Facing stage 4 metastatic melanoma while 22 weeks pregnant, Bitner underwent two brain surgeries followed by ipilimumab (Yervoy) and nivolumab (Opdivo). She achieved remission after four infusions.
Why Early Advocacy and Second Opinions Matter
Patient stories highlight a recurring theme: persistence in seeking specialized care. Gordon Levine, who faced stage 4 colorectal cancer that spread to his liver, lungs, and bones, was initially preparing to put his affairs in order. A second opinion led to a combination of ipilimumab and nivolumab. According to Levine, his tumors began “melting away,” allowing him to return to an active lifestyle. Similarly, Dana Deighton, diagnosed at 43 with esophageal cancer, successfully advocated for nivolumab after her cancer recurred despite surgery and radiation, eventually achieving remission.
Future Trends in Cancer Treatment
The field is moving toward combination therapies and personalized medicine. According to the CRI, the 20-fold increase in usage since 2011 suggests that healthcare systems are becoming more adept at identifying which patients qualify for these targeted treatments earlier in their diagnostic journey.
Pro Tip: If you or a loved one are facing a difficult diagnosis, ask your oncologist about immunotherapy options.
Frequently Asked Questions
What is the primary difference between chemotherapy and immunotherapy?
Immunotherapy works by training the body’s own immune system to find and destroy cancer cells.
Is immunotherapy available for all types of cancer?
Currently, immunotherapy is approved for more than 20 solid tumor types and five blood cancers. Research is ongoing to expand these applications to other forms of the disease.
How do patients qualify for immunotherapy?
Patients are encouraged to seek second opinions at major research centers if initial treatment options are unsuccessful.
The Cancer Research Institute (CRI), founded in 1953, is the world’s leading nonprofit organization dedicated exclusively to fueling the discovery and development of immunotherapies for all cancers. For more information on ongoing clinical trials and the latest data, visit cancerresearch.org.
Are you interested in learning more about the latest developments in oncology? Subscribe to our newsletter for monthly updates on clinical breakthroughs and patient advocacy news.
